Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Bispecific T-cell Redirectors (Tecvayli + Talvey) in Frontline High-risk Multiple Myeloma
2024-514016-26-00Phase 2Authorised
- Sponsor
- PETHEMA
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of teclistamab, talquetamab and daratumumab in multiple myeloma (MM) (2 arms), sponsored by PETHEMA. Primary endpoint: Primary MRD and CR response after Tecvayli + Darzalex therapy. Planned start Aug 2024; status: authorised.
02
Drugs
teclistamabtalquetamabdaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-514016-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514016-26-00.